Literature DB >> 9422926

Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma.

A J Foss1, I Whelehan, J L Hungerford, D F Anderson, R D Errington, A Kacperek, M Restori, J Kongerud, M Sheen.   

Abstract

AIMS/
BACKGROUND: Proton beam radiotherapy can effectively treat primary uveal melanomas of any size. Some patients, however, develop adverse late effects following treatment and the purpose of this study was to determine which factors give rise to a poor local outcome.
METHODS: The hospital records from a first cohort of 127 patients treated by protons from 1989 to 1992 were reviewed retrospectively. The presence of rubeosis was selected as a measure of significant ocular damage. Split file analysis was performed with 73 cases forming a test group with the remaining 54 cases acting as a validation group.
RESULTS: Large tumour size and the presence of retinal detachment were significant, independent risk factors for developing rubeosis for both the test and validation groups. These factors also predicted subsequent enucleation for uncontrolled ocular pain. Patients with tumours too large to plaque and with an associated retinal detachment had a 90% chance of developing rubeosis within 4 years of proton beam radiotherapy.
CONCLUSIONS: Patients with a uveal melanoma too large for plaque therapy and an associated retinal detachment run a very high risk of developing rubeosis after proton beam radiotherapy and one third of individuals developing rubeosis required enucleation for pain even if local tumour control was satisfactory.

Entities:  

Mesh:

Year:  1997        PMID: 9422926      PMCID: PMC1722306          DOI: 10.1136/bjo.81.9.748

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  25 in total

1.  Matched group study of surgical resection versus cobalt-60 plaque radiotherapy for primary choroidal or ciliary body melanoma.

Authors:  J J Augsburger; K Lauritzen; J W Gamel; D J DeBrakeleer; J C Lowry; R Eisenman
Journal:  Ophthalmic Surg       Date:  1990-10

2.  A comparison of prognostic covariates for uveal melanoma.

Authors:  J W Gamel; J B McCurdy; I W McLean
Journal:  Invest Ophthalmol Vis Sci       Date:  1992-05       Impact factor: 4.799

3.  Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation.

Authors:  J M Seddon; E S Gragoudas; D M Albert; C C Hsieh; L Polivogianis; G R Friedenberg
Journal:  Am J Ophthalmol       Date:  1985-03-15       Impact factor: 5.258

4.  Prognostic factors for metastasis following proton beam irradiation of uveal melanomas.

Authors:  E S Gragoudas; J M Seddon; K M Egan; L Polivogianis; C C Hsieh; M Goitein; L Verhey; J Munzenrider; M Austin-Seymour; M Urie
Journal:  Ophthalmology       Date:  1986-05       Impact factor: 12.079

5.  Histopathology of uveal melanomas treated with charged particle radiation.

Authors:  J B Crawford; D H Char
Journal:  Ophthalmology       Date:  1987-06       Impact factor: 12.079

6.  Risk factors for metastatic uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

7.  Predictive factors of visual outcome after local resection of choroidal melanoma.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

8.  Neovascular glaucoma after helium ion irradiation for uveal melanoma.

Authors:  M K Kim; D H Char; J L Castro; W M Saunders; G T Chen; R D Stone
Journal:  Ophthalmology       Date:  1986-02       Impact factor: 12.079

9.  Anterior segment complications after helium ion radiation therapy for uveal melanoma. Radiation cataract.

Authors:  W J Meecham; D H Char; S Kroll; J R Castro; E A Blakely
Journal:  Arch Ophthalmol       Date:  1994-02

10.  Five-year follow-up of helium ion therapy for uveal melanoma.

Authors:  D H Char; J R Castro; S M Kroll; A R Irvine; J M Quivey; R D Stone
Journal:  Arch Ophthalmol       Date:  1990-02
View more
  19 in total

1.  Where is the superiority of proton radiation for ocular tumours?

Authors:  Nikolaos E Bechrakis; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-07       Impact factor: 3.117

2.  Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window.

Authors:  S R Boyd; D Tan; C Bunce; A Gittos; M H Neale; J L Hungerford; S Charnock-Jones; I A Cree
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

3.  Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma.

Authors:  Henrike Wuestemeyer; Wolfgang Sauerwein; Daniel Meller; Pierre Chauvel; Andreas Schueler; Klaus-Peter Steuhl; Norbert Bornfeld; Gerasimos Anastassiou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-23       Impact factor: 3.117

4.  Endodrainage, Tumor Photocoagulation, and Silicone Oil Tamponade for Primary Exudative Retinal Detachment due to Choroidal Melanoma Persisting after Proton Beam Therapy.

Authors:  Ira Seibel; Dino Cordini; Gregor Willerding; Aline Isabel Riechardt; Antonia Maria Joussen
Journal:  Ocul Oncol Pathol       Date:  2014-07-22

5.  Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment.

Authors:  R M Conway; W C Chua; C Qureshi; F A Billson
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

6.  Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors.

Authors:  Aline I Riechardt; Daniel Pilger; Dino Cordini; Ira Seibel; Enken Gundlach; Annette Hager; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-18       Impact factor: 3.117

7.  Proton beam radiotherapy in the management of uveal melanoma: Clinical experience in Scotland.

Authors:  Samir Aziz; Alex Taylor; Andrzej McConnachie; Alex Kacperek; Ewan Kemp
Journal:  Clin Ophthalmol       Date:  2009-06-02

8.  Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.

Authors:  Amir Mahdjoubi; Marie Najean; Stéphanie Lemaitre; Sylvain Dureau; Rémi Dendale; Christine Levy; Livia Lumbroso-Le Rouic; Laurence Desjardins; Nathalie Cassoux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-07       Impact factor: 3.117

Review 9.  The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review.

Authors:  Geertruida E Bekkering; Anne W S Rutjes; Vasiliy V Vlassov; Daniel M Aebersold; Konrade von Bremen; Peter Jüni; Jos Kleijnen
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

10.  [Endoresection following proton beam irradiation of large uveal melanomas].

Authors:  N E Bechrakis; S Höcht; P Martus; K M Kreusel; J Heese; M H Foerster
Journal:  Ophthalmologe       Date:  2004-04       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.